Total Recovery Stack

A 2025 systematic review by Vasireddi's group (PMID 40756949) screened 544 papers on BPC-157. Thirty-six met inclusion criteria. Thirty-five were animal studies. One was clinical. That ratio says a lot about where the science stands right now. The BPC-157 peptide (Body Protection Compound-157) is a pentadecapeptide (15 amino acids) from a protective protein in human gastric juice. It promotes tissue repair through angiogenesis (VEGF-driven blood vessel growth), nitric oxide modulation, and FAK-paxillin pathway activation in tendons and ligaments. One property separates it from most peptides: it survives stomach acid. Oral dosing works, particularly for gut applications, because the peptide reaches intestinal tissue without being degraded. Animal data is reproducible across labs and species. Healing acceleration has been confirmed in tendons, ligaments, muscles, nerves, corneas, and intestinal ulcers. A 2024 intravesical case series (12 patients (n=12) with interstitial cystitis) reported 80 to 100 percent symptom resolution. A 2025 IV pilot by Lee and Burgess confirmed tolerability up to 20 mg intravenous in two adults. Community data adds a different kind of evidence. Across r/Peptides, ExcelMale, and Longecity, users have reported steady outcomes for years. Pain reduction and improved mobility within 1 to 3 weeks for soft tissue injuries. Gut symptom relief within days on oral dosing. Faster post-surgical recovery. The community figured out the standard protocol before the researchers caught up. 250 mcg subcutaneous twice daily, near the injury, for 4 to 6 weeks. BPC-157 has no FDA approval. The FDA placed it on the Category 2 bulk drug substance list in 2023, blocking compounding. On April 15, 2026, HHS Secretary Kennedy removed BPC-157 and 11 other peptides from Category 2. PCAC review begins July 2026, with compounding access projected for late 2026 to mid-2027. Compared to TB-500, BPC-157 targets local tissue repair near the injection site through angiogenesis and NO modulation. TB-500 works systemically regardless of injection location. The two are commonly paired in a 1:1 ratio for combined local and systemic coverage.

Four thousand genes. That's the number GHK-Cu flips toward repair when it binds to human cells, according to gene expression profiling by Pickart's group (PMID 25789553, 26236730). The GHK-Cu peptide (glycyl-L-histidyl-L-lysine copper(II), also written GHK:Cu or copper tripeptide-1) is a naturally occurring copper peptide found in human plasma, saliva, and urine. Plasma levels sit around 200 ng/mL at age 20 and drop to roughly 80 ng/mL by age 60. The mechanism is broad. GHK-Cu upregulates collagen I, III, and V synthesis, boosts elastin and decorin production, and recruits immune and endothelial cells to damaged tissue. The copper ion itself is required for enzymatic processes in wound remodeling. In 2024, Bian and colleagues confirmed anti-fibrotic activity in a silicosis lung model with human biomarker data (PMID 38879894), expanding the peptide's research footprint beyond skin. In practice, two routes dominate. Topical formulations (1 to 3% concentration) have cosmetic safety data going back decades; small clinical trials (n = 41 to 71) showed improved skin density and fine line reduction. Injectable use (0.5 to 2 mg/day subcutaneous) has no published dose-finding trial in humans but has one of the largest community evidence bases of any anti-aging peptide. Reports across r/Peptides, r/Biohackers, and practitioner networks describe improved skin firmness by weeks four to six; sentiment runs at 4.2 out of 5. The honest limitation: all mechanistic data is in vitro or murine. Pro-angiogenic activity flagged by the NCI raises an unresolved theoretical oncology concern. GHK-Cu is classified as research-only and is not FDA-approved for any indication.

Seven amino acids. That is all TB-500 is. Acetylated leucine-lysine-lysine-threonine-glutamate-threonine-glutamine, pulled from positions 17 through 23 of the 43-amino-acid thymosin beta-4 protein. CAS number 885340-08-9, molecular weight 846.97 Da. The mechanism is well characterized in animals. TB-500 binds monomeric G-actin, sequestering free actin subunits and remodeling the cytoskeleton so that endothelial and immune cells migrate faster to damaged tissue. It upregulates VEGF 2.5 to 3.8-fold. Malinda and colleagues confirmed that thymosin beta-4 increased reepithelialization by 42% at day 4 and 61% at day 7 versus controls in corneal wound models (PMID 10469335). It also suppresses myofibroblast differentiation, which reduces scar formation. What makes TB-500 unusual is systemic distribution. You don't need to inject near the injury. Subcutaneous injection in the abdomen reaches a torn rotator cuff the same way it reaches a strained hamstring. Community users have validated this property thousands of times over. The first fragment-specific human trial (NCT07487363) began recruiting in 2026 for an ASCVD indication with approximately 80 subjects. No results are available yet. A 2024 metabolite study by Rahaman and colleagues added a wrinkle: the parent compound showed no wound-healing activity in vitro. The metabolite Ac-LKKTE was the active species. That finding has not changed community dosing practices, but it raises questions about mechanism attribution. Community confidence (4.1/5 sentiment, 500+ r/Peptides threads) sits well ahead of the formal evidence base. TB-500 was on the FDA Category 2 list from 2024 until April 15, 2026, when HHS removed it. Compounding pharmacy access awaits PCAC review starting July 2026. All current supply comes from unregulated gray-market vendors.

KPV (Lysine-Proline-Valine, CAS 67727-97-3) is the C-terminal tripeptide of alpha-melanocyte stimulating hormone and one of the most discussed anti-inflammatory peptides in the gut health community. It doesn't bind melanocortin receptors the way full-length alpha-MSH does. Instead, it enters cells through PepT1, a di/tripeptide transporter expressed in the small intestine. The targeting gets interesting during active inflammation. PepT1 expression increases in inflamed colonic epithelium, confirmed in both Caco2-BBE cell lines and mouse colitis models (Dalmasso et al., Gastroenterology 2008, PMID 18061177). Inflamed tissue absorbs more KPV than healthy tissue. Once inside the cell, KPV inhibits NF-kB nuclear translocation at nanomolar concentrations, cutting production of TNF-alpha, IL-1beta, IL-6, and IL-8. Community use mirrors the preclinical rationale almost exactly. Oral dosing at 500 to 1,500 mcg per day on an empty stomach is the standard protocol for IBD, IBS, and leaky gut. Subcutaneous injection at 200 to 500 mcg per day covers systemic inflammation. The BPC-157 stack is the most discussed combination; KPV handles the inflammatory signaling while BPC-157 drives mucosal repair. Multiple integrative medicine clinics recommend this pairing. The honest limitation: every dose recommendation comes from mouse data extrapolation and community trial-and-error. No human pharmacokinetic study has measured oral bioavailability. No dose-finding trial has been completed. The plasma half-life (~30 minutes) is estimated from alpha-MSH family kinetics, not from direct KPV measurement. Fifteen PubMed papers cover this peptide. The FDA has stated it lacks human exposure data for any administration route. That gap between clean preclinical science and absent human validation defines where KPV sits right now.